Research ExplorerPublicationsMyeloablative megatherapy with autologous stem-cell rescue v...

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

Standard

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. / Berthold, Frank; Boos, Joachim; Burdach, Stefan; Erttmann, Rudolf; Henze, Günter; Hermann, Johann; Klingebiel, Thomas; Kremens, Bernhard; Schilling, Freimut H; Schrappe, Martin; Simon, Thorsten; Hero, Barbara.

In: LANCET ONCOL, Vol. 6, No. 9, 9, 2005, p. 649-658.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Berthold, F, Boos, J, Burdach, S, Erttmann, R, Henze, G, Hermann, J, Klingebiel, T, Kremens, B, Schilling, FH, Schrappe, M, Simon, T & Hero, B 2005, 'Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.', LANCET ONCOL, vol. 6, no. 9, 9, pp. 649-658. <http://www.ncbi.nlm.nih.gov/pubmed/16129365?dopt=Citation>

APA

Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., Simon, T., & Hero, B. (2005). Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. LANCET ONCOL, 6(9), 649-658. [9]. http://www.ncbi.nlm.nih.gov/pubmed/16129365?dopt=Citation

Vancouver

Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. LANCET ONCOL. 2005;6(9):649-658. 9.

Bibtex

@article{05fd44032ef64098807ff6d439241f8a,
title = "Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.",
abstract = "BACKGROUND: Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet its role is poorly defined. We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy. METHODS: 295 patients with high-risk neuroblastoma (ie, patients with stage 4 disease aged older than 1 year or those with MYCN-amplified tumours and stage 1, 2, 3, or 4S disease or stage 4 disease and",
author = "Frank Berthold and Joachim Boos and Stefan Burdach and Rudolf Erttmann and G{\"u}nter Henze and Johann Hermann and Thomas Klingebiel and Bernhard Kremens and Schilling, {Freimut H} and Martin Schrappe and Thorsten Simon and Barbara Hero",
year = "2005",
language = "Deutsch",
volume = "6",
pages = "649--658",
journal = "LANCET ONCOL",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

RIS

TY - JOUR

T1 - Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

AU - Berthold, Frank

AU - Boos, Joachim

AU - Burdach, Stefan

AU - Erttmann, Rudolf

AU - Henze, Günter

AU - Hermann, Johann

AU - Klingebiel, Thomas

AU - Kremens, Bernhard

AU - Schilling, Freimut H

AU - Schrappe, Martin

AU - Simon, Thorsten

AU - Hero, Barbara

PY - 2005

Y1 - 2005

N2 - BACKGROUND: Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet its role is poorly defined. We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy. METHODS: 295 patients with high-risk neuroblastoma (ie, patients with stage 4 disease aged older than 1 year or those with MYCN-amplified tumours and stage 1, 2, 3, or 4S disease or stage 4 disease and

AB - BACKGROUND: Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet its role is poorly defined. We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy. METHODS: 295 patients with high-risk neuroblastoma (ie, patients with stage 4 disease aged older than 1 year or those with MYCN-amplified tumours and stage 1, 2, 3, or 4S disease or stage 4 disease and

M3 - SCORING: Zeitschriftenaufsatz

VL - 6

SP - 649

EP - 658

JO - LANCET ONCOL

JF - LANCET ONCOL

SN - 1470-2045

IS - 9

M1 - 9

ER -